DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Chris Gibson - 2 Scott Schoenhaus - 1 Jensen Huang - 1 Leerink - 1 Mani Foroohar - 1 Foroohar - 1 Recursion's - 1 KeyBanc's Schoenhaus - 1
Top related locs:
U.S biopharma Biohive Salt Lake City , Utah
Top related orgs:
Nvidia - 2 Bayer - 2 Analysts - 1 Capital - 1 ARK Investment Management - 1 REC - 1 CCM - 1 Union - 1

Search resuls for: "AbCellera"


5 mentions found


☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
  + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
☆ Nvidia invests $50 million in biotech company Recursion for A.I. drug discovery
  + stars: | 2023-07-12 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Chipmaker Nvidia will invest $50 million in Recursion Pharmaceuticals to speed up the development of the biotech firm's artificial intelligence models for drug discovery, the companies said Wednesday. AI models usually require vast amounts of data, typically measured in terabytes, to train them. Nvidia can then potentially license those AI models on BioNeMo, the company's cloud service for generative AI in drug discovery that it rolled out earlier this year. A month later, Google Cloud launched two new AI-powered tools that aim to help biotech and pharmaceutical companies accelerate drug discovery. The company in May acquired two companies in the AI-driven drug discovery space for $87.5 million.
Persons: Roche, Chris Gibson, Nvidia's, drugmakers, Exscientia, AbCellera Biologics, — CNBC's Benjamin Taubman Organizations: Nvidia, Pharmaceuticals, Bayer, NVIDIA, Moderna, Google Cloud Locations: Salt Lake City , Utah
☆ We asked 4 expert tech investors how to invest in AI without getting sucked in by the hype. Here's what they told us.
  + stars: | 2023-02-22 | by ( Marley Jay | ) www.businessinsider.com   time to read: +9 min
Insider spoke to four tech fund managers about their ideas and approaches to the theme. This year, Open AI's ChatGPT has attracted even more hype — and much more money — as Microsoft invested $10 billion in Open AI. "Fads and themes are really common in technology," mutual fund manager Matthew Moberg told Insider. "A lot of the leading AI companies are using Cloudflare today, and we think that will increase." Michael Loukas is the CEO of TrueMark Investments, which launched its Tech, AI, and Deep Learning ETF three years ago.
☆ Follow these insiders: Some execs made a boatload in tough year buying at the right time
  + stars: | 2022-12-09 | by ( Jesse Pound | ) www.cnbc.com   time to read: +3 min
A report from data analytics firm Verity shows that some corporate insiders made stock buys this year that have already doubled in value. Many professional investors track insider buying and selling as a measure of a company's quality. Verity compiled insider-buying data from securities filings to show the best insider stock buys of the year. Some notable insiders buying at biotech companies include AbCellera Biologics CFO Andrew Booth and Iveric Bio director Calvin Roberts. The top two insider buys in the S & P 500 came from directors of Genuine Parts .
☆ FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
  + stars: | 2022-11-30 | by ( ) www.reuters.com   time to read: +1 min
Nov 30 (Reuters) - Eli Lilly and Co's COVID-19 drug bebtelovimab is not currently authorized for emergency use in the United States, the Food and Drug Administration said, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron. Wednesday's announcement takes away authorization from the last COVID-19 monoclonal antibody treatment, leaving Pfizer Inc's (PFE.N) antiviral drug Paxlovid, Merck's (MRK.N) Lagevrio and Gilead Sciences' (GILD.O) Veklury as treatments for the disease, besides convalescent plasma for some patients. AstraZeneca Plc's monoclonal antibody Evusheld is also authorized for protection against COVID-19 infection in some people. The drug, which was discovered by Abcellera (ABCL.O) and commercialized by Eli Lilly, received an authorization from the FDA in February. BQ.1 and BQ.1.1 have become the dominant strains in the United States after a steady increase in prevalence over the last two months, surpassing Omicron's BA.5 sub-variant, which had driven cases earlier in the year.
0 next >>
Total: 5